Monogram Orthopaedics (NASDAQ:MGRM) Upgraded at Roth Capital

Roth Capital upgraded shares of Monogram Orthopaedics (NASDAQ:MGRM) to a strong-buy rating in a research report report published on Monday,Zacks.com reports. Roth Capital also issued estimates for Monogram Orthopaedics’ Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.50) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.06 EPS.

Separately, Roth Mkm initiated coverage on shares of Monogram Orthopaedics in a research note on Monday. They set a “buy” rating and a $4.00 target price on the stock.

Monogram Orthopaedics Stock Down 3.0 %

NASDAQ:MGRM opened at $2.60 on Monday. The company has a market cap of $89.21 million, a price-to-earnings ratio of -5.53 and a beta of 2.00. Monogram Orthopaedics has a 52 week low of $1.53 and a 52 week high of $4.90. The company has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.40.

Hedge Funds Weigh In On Monogram Orthopaedics

Large investors have recently bought and sold shares of the business. Barclays PLC purchased a new stake in shares of Monogram Orthopaedics during the 3rd quarter worth approximately $29,000. State Street Corp purchased a new stake in Monogram Orthopaedics in the third quarter valued at $62,000. Finally, Geode Capital Management LLC boosted its stake in Monogram Orthopaedics by 1,267.4% in the third quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock valued at $557,000 after acquiring an additional 194,776 shares in the last quarter. Hedge funds and other institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.